TOKYO and CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A….Original Article
FDA Grants Traditional Approval for Leqembi (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
